Central Nervous System Diseases  >>  Replagal (agalsidase alfa)  >>  Phase N/A
Welcome,         Profile    Billing    Logout  

2 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Replagal (agalsidase alfa) / Samaritan Pharma, Takeda
NCT01745185: Immune Response in Subjects With Fabry Disease Who Are Switching From Agalsidase Alfa to Agalsidase Beta

Completed
N/A
30
US
O & O Alpan LLC
Fabry Disease
04/15
08/16
NCT02969200: Fabry: Renal Function During Long-term ERT by 51Cr-EDTA Clearance

Completed
N/A
52
Europe
Enzyme replacement therapy, Fabrazyme (agalsidase beta), Replagal (agalsidase alfa)
Ulla Feldt-Rasmussen
Fabry Disease
09/16
12/16

Download Options